Sitemap > Breaking Research > Cardiovascular Disorders
Displaying 351 - 400 of 4862 results
- Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis.
- Hepatocyte growth factor suppresses vascular medial hyperplasia and matrix accumulation in advanced pulmonary hypertension of rats.
- Novel antiinflammatory vascular benefits of systemic and stent-based delivery of ethylisopropylamiloride.
- A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
- Long-term treatment with a phosphodiesterase type 5 inhibitor improves pulmonary hypertension secondary to heart failure through enhancing the natriuretic peptides-cGMP pathway.
- Effects of intracerebroventricular application of brain-derived neurotrophic factor on cerebral recovery after cardiac arrest in rats.
- NO-sartans: a new class of pharmacodynamic hybrids as cardiovascular drugs.
- Vascular endothelial growth factor stimulates skeletal muscle regeneration in vivo.
- The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates.
- Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation.
- Small proline-rich protein 1A is a gp130 pathway- and stress-inducible cardioprotective protein.
- Inhalation of carbon monoxide prevents liver injury and inflammation following hind limb ischemia/reperfusion.
- Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis.
- Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.
- Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial.
- Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
- Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.
- Cyclooxygenase-2 and an early stage of chronic hypoxia-induced pulmonary hypertension in newborn pigs.
- Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
- VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
- Comparison of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of onset versus at later times.
- Class effect of angiotensin-converting enzyme inhibitors on prevention of myocardial infarction.
- Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial.
- Myocardial protective effect of FR167653; a novel cytokine inhibitor in ischemic-reperfused rat heart.
- The regulated long-term delivery of therapeutic proteins by using antigen-specific B lymphocytes.
- Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction.
- Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype.
- Hyperinsulinaemia is associated with increased long-term mortality following acute myocardial infarction in non-diabetic patients.
- Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative.
- Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial.
- Calpain inhibitor-1 protects the rat heart from ischemia-reperfusion injury: analysis by mechanical work and energetics.
- PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs.
- Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets.
- Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice.
- An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.
- Galantamine blocks cloned Kv2.1, but not Kv1.5 potassium channels.
- Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis.
- Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial.
- Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic.
- Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
- Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction.
- Beyond hypertension toward guidelines for cardiovascular risk reduction.
- Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury.
- Adeno-associated viral vector delivers cardiac-specific and hypoxia-inducible VEGF expression in ischemic mouse hearts.
- Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.
- Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
- Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist.
- AT2-selective angiotensin II analogues containing tyrosine-functionalized 5,5-bicyclic thiazabicycloalkane dipeptide mimetics.
- Highly potent 1-aminocyclohexane-1-carboxylic acid substituted V2 agonists of arginine vasopressin.
- HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 Next >